Trastuzumab News and Research

RSS

FDA grants accelerated approval to Perjeta for neoadjuvant treatment of breast cancer

The U.S. Food and Drug Administration today granted accelerated approval to Perjeta (pertuzumab) as part of a complete treatment regimen for patients with early stage breast cancer before surgery (neoadjuvant setting). Perjeta is the first FDA-approved drug for the neoadjuvant treatment of breast cancer.

1 Oct 2013

FDA Panel Urges Fast Approval Of Perjeta For Early-Stage Breast Cancer

...

13 Sep 2013

Roche's Herceptin formulation wins EU approval for treatment of HER2-positive breast cancer

Halozyme Therapeutics, Inc. announced today that the European Commission has granted Roche European Union marketing authorization for the use of a time-saving subcutaneous formulation of Herceptin (trastuzumab) for the treatment of HER2-positive breast cancer.

2 Sep 2013

ImmunoGen reports net loss of $21.9 million in Q4 2013

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload antibody-drug conjugate technology, today reported financial results for the three-month period and fiscal year ended June 30, 2013. ImmunoGen also provided guidance for its 2014 fiscal year and an update on the Company.

2 Aug 2013

EORTC starts phase 2 trial in elderly patients with HER-2 positive metastatic breast cancer

Despite the fact that the incidence of cancer is many fold higher in persons over 65 years of age, we still have an inadequate understanding on how best to treat these older cancer patients. Furthermore, even though elderly patients are occasionally included in clinical trials, those elderly patients who are eventually included are mostly 'healthy' (fit) elderly patients.

20 Jun 2013

Combination of cell-killing radioactive particle and antibody is safe for treating cancers

An experimental treatment that combines a cell-killing radioactive particle with an antibody that homes in on cancer cells is safe in the treatment of cancers spreading through patients' abdomens, according to data from a first-in-human study presented today at the Society of Nuclear Medicine and Molecular Imaging annual meeting in Vancouver.

11 Jun 2013

Everolimus reverses trastuzumab resistance in early HER-2 positive breast cancer

A study that aimed to understand how the cancer drug everolimus helps overcome the resistance breast cancers can develop to trastuzumab has left researchers contemplating a puzzle.

3 May 2013

Study suggests lung cancer patients with HER2 mutations may benefit from anti-HER2 drugs

New results from a retrospective study conducted in Europe suggest that anti-HER2 treatments, like the widely used breast cancer agent trastuzumab (Herceptin), have anti-cancer effects in a small subset of patients with advanced non-small cell lung cancer (NSCLC) harboring specific HER2 protein mutations.

23 Apr 2013

Michigan's first cardio-oncology clinic launched to prevent heart problems

As cancer therapy becomes more effective and the number of cancer survivors increases, doctors are faced with a new challenge: ensuring patients have a healthy heart to enjoy the rest of their lives.

16 Apr 2013

New data on use of PBD dimers as warheads in ADCs presented at AACR annual meeting

Spirogen, a leading oncology-focused company developing DNA sequence targeted agents, and BioAtla LLC, a San Diego headquartered antibody therapeutics developer, today announced new data on the use of pyrrolobenzodiazepine (PBD) dimers as warheads in antibody drug conjugates (ADCs) at the annual meeting of the American Association for Cancer Research (AACR) in Washington, DC.

11 Apr 2013

ImmunoGen discloses preclinical data for EGFR-targeting ADC, IMGN289

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer therapeutics using its Targeted Antibody Payload technology, disclosed for the first time today preclinical data for its EGFR-targeting ADC, IMGN289.

11 Apr 2013

Research shows omega-3 fatty acids stop proliferation of triple-negative breast cancer cells

Researchers from Fox Chase Cancer Center have found that omega-3 fatty acids and their metabolite products slow or stop the proliferation, or growth in the number of cells, of triple-negative breast cancer cells more effectively than cells from luminal types of the disease.

10 Apr 2013

Subcutaneous administration of Herceptin preferred by HER2-positive breast cancer patients over IV

Results from the PrefHer (Patient Preference for Subcutaneous (SC) versus Intravenous (IV) Herceptin) trial show that 92% of early HER2-positive breast cancer patients favoured quicker SC administration of Herceptin compared to the standard IV infusion.1 Presented at the St. Gallen Breast Cancer Conference in Switzerland.

15 Mar 2013

African-American women with breast cancer more likely to develop heart failure

African-American women who survive breast cancer are more likely to develop heart failure than other women who have beaten the disease, according to research being presented at the American College of Cardiology's 62nd Annual Scientific Session.

8 Mar 2013

PDL BioPharma fourth quarter total revenues increase to $86.0 million

PDL BioPharma, Inc. (PDL) today reported financial results for the fourth quarter and full year ended December 31, 2012.

2 Mar 2013

Engineering chemotherapy drugs' shape increases their ability to target and inhibit cancer cells

Bioengineering researchers at University of California, Santa Barbara have found that changing the shape of chemotherapy drug nanoparticles from spherical to rod-shaped made them up to 10,000 times more effective at specifically targeting and delivering anti-cancer drugs to breast cancer cells.

28 Feb 2013

Trastuzumab News and Research

FDA grants accelerated approval to Perjeta for neoadjuvant treatment of breast cancer

FDA Panel Urges Fast Approval Of Perjeta For Early-Stage Breast Cancer

Roche's Herceptin formulation wins EU approval for treatment of HER2-positive breast cancer

ImmunoGen reports net loss of $21.9 million in Q4 2013

EORTC starts phase 2 trial in elderly patients with HER-2 positive metastatic breast cancer

Combination of cell-killing radioactive particle and antibody is safe for treating cancers

Everolimus reverses trastuzumab resistance in early HER-2 positive breast cancer

Study suggests lung cancer patients with HER2 mutations may benefit from anti-HER2 drugs

Michigan's first cardio-oncology clinic launched to prevent heart problems

New data on use of PBD dimers as warheads in ADCs presented at AACR annual meeting

ImmunoGen discloses preclinical data for EGFR-targeting ADC, IMGN289

Research shows omega-3 fatty acids stop proliferation of triple-negative breast cancer cells

Subcutaneous administration of Herceptin preferred by HER2-positive breast cancer patients over IV

African-American women with breast cancer more likely to develop heart failure

PDL BioPharma fourth quarter total revenues increase to $86.0 million

Engineering chemotherapy drugs' shape increases their ability to target and inhibit cancer cells

New, effective and less toxic therapeutic option for patients with HER2-positive breast cancer

Genentech receives FDA approval for Kadcyla to treat HER2-positive metastatic breast cancer

Antibody-drug conjugates (ADCs): an interview with Dr Marco Timmers, CSO at Synthon Biopharmaceuticals

Synthon Biopharmaceuticals announces promising results with its antibody-drug conjugate program

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News